The first results of using the combined drug rilpivirine/tenofovir/emtricitabine in Russian patients with HIV infection in real clinical practice

Sizova N.V., Volova L.Yu., Malyuzhenko I.V., Isaeva G.N., Koveleno A.Yu., Minaeva S.V., Topolskaya S.V., Voronin E.E., Okhonskaya L.V.

1Center for Prevention and Control of AIDS and Communicable Diseases, Saint Petersburg; 2Yamal-Nenets District Center for AIDS Prevention and Control, Noyabrsk; 3Volgograd Regional Center for Prevention and Control of AIDS and Communicable Diseases; 4Leningrad Regional Center for Prevention and Control of AIDS and Communicable Diseases, St. Petersburg; 5Nizhny Novgorod Regional Center for Prevention and Control of AIDS and Communicable Diseases, Nizhniy Novgorod; 6Nizhny Novgorod Medical Academy, Ministry of Health of Russia, Nizhny Novgorod; 7Clinical Center for AIDS Prevention and Control, Ministry of Health of the Krasnodar Territory, Krasnodar; 8Republican Clinical Hospital of Infectious Diseases of Ministry of Health of Russia, Ust-Izhora Settlement, Saint Petersburg
Objective. To evaluate the efficacy, safety, and tolerability of the combined drug rilpivirine/tenofovir/emtricitabine (RPV/TDF/FTC – еviplera) in Russian patients with a viral load (VL) of lower than 100 000 copies/ml.
Subjects and methods. The data on 29 adult HIV-infected patients were analyzed. VH changes and CD4+ lymphocyte counts were estimated 6 months after initiation of RPV/TDF/FTC therapy and the pattern of blood laboratory values were assessed.
Results. Six months after the therapy, 68.2% of the patients remained virologically suppressed; HIV RNA levels were decreased in 27.3% (the baseline VN was unsuppressed) and increased only in one patient. The median increase in CD4+ lymphocytes was 50.5 (0–535) cells/µl at 24 week. Adverse events and significant increases in hepatic enzymes and lipids were not observed; there was a slight decrease in the levels of total cholesterol, triglycerides, and glucose.
Conclusion. Eviplera (RPV/TDF/FTC) combines a complete once-daily, single-tablet antiretroviral therapy regimen. The drug has demonstrated the high virologic and immunologic efficacy 6 months after treatment and no negative effect on liver function (also in HIV/HCV or HIV/HBV-coinfected patients), lipid profile, good tolerability profile, absence of CNS and gastrointestinal adverse reactions.


1. d'Arminio Monforte A., Lepri A.C., Rezza G., Pezzotti P., Antinori A., Phillips A.N., Angarano G., Colangeli V., De Luca A., Ippolito G., Caggese L., Soscia F., Filice G., Gritti F., Narciso P., Tirelli U., Moroni M. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000; 14(5): 499–507.

2. Belyakov N.A., Zakharova N.G., Sizova N.V. (red.). Ekonomicheskie i klinicheskie voprosy VICh-infekcii. Tematicheskij arxiv [Economical and clinical questions of HIV infection. Theme archive]. St. Peterburg: Baltijskij medicinskij obrazovatel'nyj centr, 2014. 210 p. (In Russ.)

3. Komarova I.V. Serdechno-sosudistyj risk u VICh-inficirovannyh pacientov [Cardio vascular risk in HIV infectious patients]. Cand. Med. Dis. Moscow, 2014. (In Russ.)

4. Dube M., Fenton M. Lipid abnormalities. Clin. Infect. Dis. 2003; 36(Suppl 2): 79–83.

5. Kravchenko A.V., Gankina N.Yu., Kanestri V.G. [Features of antiretroviral therapy in patients with co-infection HIV and viral hepatitis]. Farmateka 2008; 19(173): 10–18. (In Russ.)

6. Kanestri V.G. Bezopasnost' i perenosimost' sovremennyh skhem antiretrovirusnoj terapii u vzroslyh bol'nyh VICH-infekciej [Safety and tolerability of modern antiretroviral therapy in adult HIV patients]. Dr. Med. Dis. Moscow, 2014. (In Russ.)

7. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, World Health Organization, 2013.

8. Guidelines of European AIDS Clinical Society (version 7.1, 2014). http://

9. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 (updated November 2013).

10. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (Last updated: April 8, 2015) http://www.

11. Mazus A.I., Kaminskij G.D., Zimina V.N., Bessarab T.P., Pronin A.Yu., Cyganova E.V., Ol'shanskij A.Yu., Goloxvastova E.L., Carenko S.P., Shimonova T.E., Petrosyan T.R., Xalilulin T.R., Orlova-Morozova E.A., Serebryakov E.M., Nabiullina D.R., Ivanova T.V. Nacional'nye klinicheskie rekomendacii po diagnostike i lecheniyu VICH-infekcii u vzroslyh [National clinical guidelines on diagnostic and treatment of HIV infectionin adult patients]. Moscow, 2014. 75 p. (In Russ.)

12. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Kanestri V.G., Afonina L.Yu., Ermak T.N., Buravcova E.V., Shaxgil'dyan V.I., Kozyrina N.V., Narsiya R.S., Zimina V.N., Pokrovskaya A.V., Efremova O.S. [The protocols of follow-up and treatment of patients with HIV infection]. Epidemiologiya i Infektsionnyie Bolezni. Aktualnyie Voprosyi 2014; 6(prilozhenie). 48 р. (In Russ.)

13. Cohen C., Bloch M., Wohl D., Arribas J., Henry K., Van Lunzen J., Towner W., Wilkins E., Garner W., Porter D., Temme L., Scharen-Guivel V., Bosse M., Rogatto F., Piontkowsky D. STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains noninferiority to efavirenz/emtricitabine/tenofovir DF in ART-naive adults through week 96 with a favourable safety profile for abnormal dreams and dizziness [poster no. WEPE064]. In: 20th International AIDS Conference. 20–25 Jul 2014, Melbourne.

14. Behrens G., Rijnders B., Nelson M., Orkin C., Cohen C., Mills A., Elion R., Vanveggel S., Stevens M., Rimsky L., Thorpe D., Bosse M., White K., Zhong L., DeMorin J., Chuck S. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA B100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS 2014; 28(4): 168–175.

15. Palella F. Jr., Fisher M., Tebas P., Gazzard B., Ruane P., van Lunzen J., Shamblaw D., Flamm J., Ebrahimi R., Porter D., White K., Hindman J., Elbert E., De-Oertel S., Fralich T. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS 2014; 28(3): 335–344.

16. Emma D. Deeks Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection. Drugs 2014; 74: 2079–2095.

17. Bernardini C., Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection. Patient Prefer Adherence. 2013; 7: 531–542.

18. Kulikov A.Yu., Babij V.V. [Pharmacoeconomic analysis of Eviplera (rilpivirine/rtenofovir/emtricitabine) in the treatment of HIV/AIDS in the Russian Federation]. Farmakoehkonomika. Teorija i praktika 2015; 3(1): 35–43. (In Russ.)

About the Autors

For correspondence:
Sizova Natalia Vladimirovna, MD; Head, Outpatient Infection Department, Center for Prevention and Control of AIDS and Communicable Diseases, Saint Petersburg; Assistant Professor, Department of Social Infections, Acad. I.P. Pavlov First Saint Petersburg State Medical University
Address: 179а, Obvodnoy Kanal Embankment, Saint Petersburg 190103
Telephone: +7 (812) 407-83-25

Similar Articles

Бионика Медиа